Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1539-1569

  Recht, A ^a   Edge, S B ^a   Solin, L J ^a   Robinson, D S ^a   Estabrook, A ^a   Fine, R E ^a   Fleming, G F ^a   Formenti, S ^a   Hudis, C ^a   Kirshner, J J ^a   Krause, D A ^a   Kuske, R R ^a   Langer, A S ^a   Sledge G W , Jr ^a   Whelan, T J ^a   Pfister, D G ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; BRACHIAL PLEXUS INJURY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LEUKEMIA; LYMPH NODE METASTASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; META ANALYSIS; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PNEUMONIA; RIB FRACTURE; SARCOMA;

EID: 0035282070     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1539     Document Type: Article

References (253)

1. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy
2. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials
3. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
4. The return (?) of postmastectomy radiotherapy
5. Local management of invasive breast cancer
6. Defining the role of post-mastectomy radiotherapy: The new evidence
7. Postmastectomy radiotherapy: Then and now
8. Consensus statement on postmastectomy radiation therapy
9. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
10. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
11. Postmastectomy radiotherapy: Questions for the twenty-first century
12. The Canadian task force on the periodic health examination
13. Rules of evidence and clinical recommendations on the use of antithrombotic agents
14. Rules of evidence and clinical recommendations on the use of antithrombotic agents
15. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
16. A decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy for high-risk breast cancer
17. Cost-effectiveness analysis of post-mastectomy locoregional radiotherapy (LRRT) for node positive (NP) stage II breast cancer patients
18. A cost-outcome analysis of adjuvant post-mastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients
19. Assessing the cost-effectiveness of postmastectomy radiation therapy
20. Patients' assessment of adjuvant treatment in operable breast cancer
21. Breast irradiation postlumpectomy: Development and evaluation of a decision instrument
22. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: Applicability of trade-off methods to policy-making
23. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer
24. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy
25. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public
26. Postmastectomy radiotherapy in the management of operable breast cancer
27. Postmastectomy radiation (RT) outcome in node (N) positive breast cancer patients among N 1-3 versus N4+ subset: Impact of extracapsular spread (ES): Update of the British Columbia randomized trial
28. The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM Stage II: The South Sweden Breast Cancer Trial
29. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial
30. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis
31. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy
32. Local-regional recurrence in breast cancer after mastectomy and Adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy
33. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer
34. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy
35. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group
36. Survival gains of locoregional radiation (RT) in breast cancer with 1-3 positive axillary nodes (N1-3): Locoregional recurrences (LocRecs) are NOT a useful guide to predict the benefit of the RT - An update from the British Columbia (BC) randomized trial
37. Adjuvant radiotherapy and chemotherapy in breast cancer
38. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group (SEG) trial
39. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy
40. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses
41. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
42. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer
43. Comparison of adjuvant postoperative radio-therapy and multiple-drug chemotherapy (CMF-VP) in operable breast cancer patients with more than four positive axillary lymph nodes
44. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer
45. Local recurrence after mastectomy in patients with T3N0 breast carcinoma treated without postoperative irradiation
46. Post-mastectomy radiotherapy in pT3N0M0 breast cancer: Is it needed?
47. Adjuvant post-operative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer
48. The role of radiotherapy in the management of operable locally advanced breast cancer: Results of a randomized trial by the Eastern Cooperative Oncology Group
49. Locally advanced (noninflammatory) carcinoma of the breast: Results and comparisons of various treatment modalities
50. Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer
51. Selection of therapy for stage III breast cancer
52. Treatment of locally advanced and inflammatory breast cancer
53. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma
54. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: A phase II trial of neoadjuvant MVAC, surgery, and radiation
55. Local recurrence after simple mastectomy
56. Modified radical mastectomy or how to achieve optimal loco-regional control in larger breast cancers
57. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
58. Prognostic value of p53 for local failure in mastectomy treated breast cancer patients
59. Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy
60. Local recurrence and the deep resection margin in carcinoma of the breast
61. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger
62. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer
63. Locoregional recurrence and extranodal extension in patients receiving systemic therapy for axillary node positive breast cancer
64. Is an axillary boost necessary in node positive stage II disease in the presence of microscopic extracapsular extension?
65. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy
66. Extracapsular axillary nodal extension (ECE) in breast cancer: Patterns of recurrence, arm edema, and survival after mastectomy with and without irradiation
67. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
68. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: An Intergroup study
69. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
70. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-22
71. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
72. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients: An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) Trial
73. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian trial
74. Randomized trial evaluating postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Results from the DBCG 82c trial
75. Tamoxifen for early breast cancer: An overview of the randomized trials
76. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
77. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group
78. Postoperative radiotherapy in the treatment of breast cancer: Results of the NSABP clinical trial
79. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast
80. Breast conservation is the treatment of choice in small breast cancer: Long-term results of a randomized trial
81. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data
82. Postoperative radiotherapy in breast cancer: Long-term results from the Oslo study
83. Local-regional recurrence after mastectomy or breast-conserving therapy
84. Long-range results for breast cancer patients treated by radical mastectomy and postoperative radiation without adjuvant chemotherapy: An update
85. Multimodal treatment for inflammatory breast cancer
86. Twice-daily fractionation for inflammatory breast cancer: The effectiveness of dose escalation
87. Postmastectomy radiation and adjuvant systemic therapy: Outcomes in high-risk women with stage II-III breast cancer and assessment of clinical, pathologic, and treatment-related factors influencing local-regional control
88. Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence
89. Axillary lymph nodes and breast cancer: A review
90. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma
91. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer
92. The impact of extracapsular axillary nodal extension (ECE) with and without irradiation on patterns of failure and survival from breast cancer
93. Flow cytometry analysis and prediction of loco-regional recurrences after mastectomy in breast carcinoma
94. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with ≥ 10 positive axillary lymph nodes
95. Rechérches sur les métastases microscopiques des cancers du sein dans les ganglions lymphatiques parasternaux et susclaviculaires
96. The incidence of supraclavicular failure in patients with T1-2 breast cancer and four or more positives nodes treated by conservative surgery and tangential breast irradiation without regional nodal irradiation
97. Carcinoma of the breast
98. Radical mastectomy versus radical mastectomy plus internal mammary dissection: Five-year results of an international cooperative study
99. Inefficacy of internal mammary nodes dissection in breast cancer surgery
100. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes
101. À propos de 195 curages mammaires internes pour cancer du sein
102. An analysis of 1242 cases of extended radical mastectomy
103. A multivariate analysis of en bloc extended radical mastectomy versus conventional radical mastectomy in operable breast cancer
104. Risk of internal mammary lymph node metastases and its prognostic value in breast cancer patients
105. Place du curage mammaire interne dans la stratégie moderne du traitment du cancer du sein operable
106. A clinical trial in the management of operable cancer of the breast
107. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
108. Significance of internal mammary lymph node metastases in breast cancer
109. The influence of untreated internal mammary metastases upon the course of mammary cancer
110. Three-dimensional internal mammary lymphoscintigraphy: Implications for radiation therapy treatment planning for breast carcinoma
111. Long-term effect of internal mammary chain treatment: Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes
112. No benefit to intentionally targeting the internal mammary lymph nodes in conservatively managed breast cancer patients
113. The dissection of internal mammary nodes does not improve the survival of breast cancer patients: 30-year results of a randomized trial
114. Efficacy of loco-regional lymph nodes irradiation after mastectomy for breast cancer with biopsy proven lymph nodes metastases: A randomized study
115. Tangential breast irradiation with or without internal mammary chain irradiation: Results of a randomized trial
116. Role of irradiation of internal mammary chain after mastectomy: A French S.F.R.O. phase III randomized trial
117. Effect of delay in radiation in the combined modality treatment of breast cancer
118. Adjuvant combined modality treatment in high risk breast cancer patients: Ten years results
119. Analysis of outcomes for high risk breast cancer patients based on interval from surgery to postmastectomy radiation therapy
120. Sequential or simultaneous chemo-radiotherapy in operable breast cancer: A French multicentric phase III study - State of inclusions
121. A randomized trial of adjuvant chemotherapy (CT) with or without radiation therapy (RT) for stage II breast cancer: 11 year follow-up of Piedmont Oncology Association Protocol 74176
122. Effect of radiotherapy in addition to 6 cycles CMF in node positive breast cancer patients
123. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer
124. Breast cancer adjuvant therapy trials at the Arizona Cancer Center using Adriamycin and cyclophosphamide
125. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer
126. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients
127. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage node-positive breast cancer: Sequencing, timing, and outcome
128. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer
129. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
130. The combination of radiotherapy and chemotherapy: A review
131. Sequencing of irradiation and chemotherapy for early-stage breast cancer
132. Radiochemotherapy after breast-conserving surgery in high-risk breast cancer
133. Post-operative radiotherapy and concomitant adjuvant chemotherapy for breast carcinoma
134. Traitement adjuvant des cancers du sein par radiochimiothérapie concomitante: Étude d'une nouvelle alternative stratégique dans les stades I et II
135. Enhanced toxicity of radiotherapy due to epirubicin containing adjuvant chemotherapy in breast carcinoma patients
136. Concurrent paclitaxel and radiation therapy for breast cancer
137. Increased risk of radiation pneumonitis in breast cancer patients treated by concomitant Taxol and radiation therapy
138. Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer (LABC): Molecular determinants of pathological response
139. Feasibility of concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in the management of locally advanced breast cancer
140. Phase I-II study of concurrent irradiation and multi-drug chemotherapy in advanced carcinoma of the breast: A pilot study by the Southeastern Cancer Study Group
141. Postmastectomy morbidity after combination preoperative irradiation and chemotherapy for locally advanced breast cancer
142. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy
143. Six-year results of a multimodality treatment strategy for locally advanced breast cancer
144. Concurrent CMF and radiation therapy for early stage breast cancer: Results of a pilot study
145. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomas
146. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil
147. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer
148. Protocole de traitement du cancer du sein localement évolué par radiochimiothérapie concomitante néoadjuvante 5FU-Taxol-FEC 100 + RT + chirugie
149. Lokalrezidivrate und überleben bei patientinnen mit brustrekonstruktion nach mastectomie
150. Oncological aspect of immediate breast reconstruction in mastectomy patients
151. Comparison of postoperative wound complications and early cancer recurrence between patients undergoing mastectomy with or without immediate breast reconstruction
152. Skin-sparing mastectomy: Oncologic and reconstructive considerations
153. Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominus musculocutaneous (TRAM) flap
154. Radiotherapy and breast reconstruction: Clinical results and dosimetry
155. Breast reconstruction with myocutaneous flaps in previously irradiated patients
156. TRAM flap breast reconstruction after radiation treatment
157. Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction
158. Radiation tolerance of transverse rectus abdominus myocutaneous-free flaps used in immediate breast reconstruction
159. Reconstruction and the irradiated breast: Is there a role for implants?
160. Treatment outcome with radiation therapy after breast augmentation or reconstruction in patients with primary breast carcinoma
161. The complications of tissue expansion in breast reconstruction: A review of 75 cases
162. Breast reconstruction in previously irradiated patients using tissue expanders and implants: A potentially unfavorable result
163. The impact of adjuvant radiotherapy and cytotoxic chemotherapy on the outcome of immediate breast reconstruction by tissue expansion after mastectomy for breast cancer
164. Immediate breast reconstruction in two stages using textured, integrated-valve tissue expanders and breast implants: A retrospective review of 171 consecutive breast reconstructions from 1989 to 1996
165. Conservation treatment of early breast cancer: Long term results and complications
166. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy
167. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy
168. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy
169. Late treatment related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone
170. Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy?
171. Diagnosis and management of brachial plexus lesions in cancer patients
172. Management of radiation-induced brachial plexus neuropathy
173. Primary breast cancer: Complications of axillary management
174. A prospective clinical trial of post-operative radiotherapy delivered in three fractions per week versus two fractions per week in breast carcinoma
175. Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy
176. Influence of dose-rate and dose per fraction on clinical outcome of breast cancer treated by external beam irradiation plus iridium-192 implants: Analysis of 289 cases
177. Radiation-induced brachial plexus injury: Follow-up of two different fractionation schedules
178. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer
179. Tolerance of normal tissues to therapeutic irradiation
180. Pulmonary effects of radiation therapy
181. The pulmonary effects of thoracic irradiation
182. Pulmonary toxicity of antineoplastic therapy
183. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy
184. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicinftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomized trial
185. A descriptive study of pulmonary complications after postoperative radiation therapy in node-positive stage II breast cancer
186. Radiotherapy for the prevention of local-regional recurrence in high risk patients post mastectomy receiving adjuvant chemotherapy
187. Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer
188. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel
189. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer
190. Radiotherapy-related lung fibrosis enhanced by tamoxifen
191. Cardiovascular mortality in a randomized trial of adjuvant radiation versus surgery alone in primary breast cancer
192. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer
193. Postoperative radiotherapy and late mortality: Evidence from the Cancer Res Campaign trial for early breast cancer
194. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry
195. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance. Epidemiology, and End Results cancer registries
196. Put the "hockey stick" on ice
197. Cardiac doses in post-operative breast irradiation
198. Dose to the cardiac vascular and conduction systems in primary breast irradiation
199. Postmastectomy radiotherapy: Toxicities and techniques to reduce them
200. Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomized trials
201. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques
202. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation
203. Mortality from myocardial infarction following posflumpectomy radiotherapy for breast cancer. A population-based study in Ontario, Canada
204. Cardiac effects of adjuvant doxorubicin and radiation therapy in node positive breast cancer patients
205. Carcinogenic effects of radiotherapy for breast cancer
206. Post-treatment sarcomas
207. Radiation therapy and breast conservation: Cosmetic results and complications
208. Late effects of adjuvant therapy for breast cancer
209. Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation
210. Long-term risk of sarcoma following radiation treatment for breast cancer
211. Soft tissue sarcoma after treatment for breast cancer
212. Soft tissue sarcoma after treatment for breast cancer: A Swedish population-based study
213. Lung cancer after radiation therapy for breast cancer
214. Increased risk of lung cancer following breast cancer radiotherapy (RT) in cigarette smokers
215. Second cancer following cancer of the breast in Connecticut
216. Radiation therapy for breast cancer and increased risk of esophageal carcinoma
217. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative therapy: The NSABP experience
218. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer
219. Leukemia risk following radiotherapy for breast cancer
220. Risk of leukemia after chemotherapy and radiation treatment for breast cancer
221. A randomized study of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer: Eleven year follow-up of a Piedmont Oncology Association trial
222. Adjuvant doxorubicin, vincristine, cyclophosphamide, fluorouracil (AVCF) for breast cancer (BC): Leukemia at 13-year follow-up
223. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
224. Leukemia in patients with breast cancer following adjuvant chemotherapy and/or postoperative radiation therapy
225. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience
226. Consecutive primary carcinomas of the breast
227. Second primary cancers of the breast: Incidence and risk factors
228. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy
229. Risk of contralateral breast cancer in Denmark 1943-80
230. Cancer in the contralateral breast after radiotherapy for breast cancer
231. Dose to the contralateral breast due to primary breast irradiation
232. Prognosis of BRCA1 hereditary breast cancer
233. Incidence of cancer in 161 families affected by ataxia telangectasia
234. Absence of linkage to the ataxia telangectasia locus in familial breast cancer
235. Molecular genotyping shows that ataxia-telangectasia heterozygotes are predisposed to breast cancer
236. Heterozygous ATM mutations do not contribute to early onset of breast cancer
237. Prevalence of ataxia-telangectasia heterozygosity in patients developing contralateral breast cancer following treatment with conservative surgery and radiation therapy
238. Ionizing radiation, breast cancer, and ataxia-telangectasia
239. Breast cancer and radiotherapy in ataxia-telangectasia heterozygote
240. Radiosensitivity of normal tissues in ataxia-telangectasia heterozygotes
241. Heterozygosity for mutations in the ataxia telangectasia gene is not a major cause of radiotherapy complications in breast cancer patients
242. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
243. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast-conserving therapy
244. Standards for breast-conservation treatment
245. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases
246. Scleroderma: A possible contraindication to lumpectomy and radiotherapy in breast carcinoma
247. Breast conservation therapy: Severe breast fibrosis after radiation therapy in patients with collagen-vascular disease
248. Acute and late reactions to radiation therapy in patients with collagen vascular diseases
249. Mixed connective tissue disease and radiation toxicity: A case report
250. An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer
251. Adjuvant chemotherapy and radiation therapy vs. chemotherapy alone for stage II breast cancer patients
252. Phase III study: Adjuvant chemotherapy versus adjuvant radiotherapy plus chemotherapy in women with node-positive breast cancer
253. Consecutive radiation and chemotherapy in the adjuvant treatment of operable breast cancer